139 related articles for article (PubMed ID: 32917538)
21. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Lu F; Hou Y; Chen Z; Jiang J; He X; Xia Y; Cao K; Chang L; Li W
Technol Cancer Res Treat; 2021; 20():15330338211016369. PubMed ID: 33977814
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
Cao L; Yao GY; Liu MF; Chen LJ; Hu XL; Ye CS
PLoS One; 2015; 10(12):e0145442. PubMed ID: 26717149
[TBL] [Abstract][Full Text] [Related]
24. Taxanes for adjuvant treatment of early breast cancer.
Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
[TBL] [Abstract][Full Text] [Related]
25. Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology appraisal.
Chilcott J; Lloyd Jones M; Wilkinson A
Health Technol Assess; 2009 Jun; 13 Suppl 1():7-13. PubMed ID: 19567208
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
27. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
28. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
29. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X
BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant platinum-based chemotherapy for early stage cervical cancer.
Rosa DD; Medeiros LR; Edelweiss MI; Bozzetti MC; Pohlmann PR; Stein AT; Dickinson HO
Cochrane Database Syst Rev; 2009 Jul; (3):CD005342. PubMed ID: 19588370
[TBL] [Abstract][Full Text] [Related]
31. Neo-adjuvant therapy for triple-negative breast cancer: Insights from a network meta-analysis.
Miyashita H; Satoi S; Cruz C; Malamud SC
Breast J; 2020 Sep; 26(9):1717-1728. PubMed ID: 32657479
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
33. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis.
Chen Y; Shi XE; Tian JH; Yang XJ; Wang YF; Yang KH
Medicine (Baltimore); 2018 May; 97(20):e10634. PubMed ID: 29768327
[TBL] [Abstract][Full Text] [Related]
34. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.
Boyne DJ; Cuthbert CA; O'Sullivan DE; Sajobi TT; Hilsden RJ; Friedenreich CM; Cheung WY; Brenner DR
JAMA Netw Open; 2019 May; 2(5):e194154. PubMed ID: 31099875
[TBL] [Abstract][Full Text] [Related]
35. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
36. Sequencing of chemotherapy and radiotherapy for early breast cancer.
Hickey BE; Francis DP; Lehman M
Cochrane Database Syst Rev; 2013 Apr; (4):CD005212. PubMed ID: 23633328
[TBL] [Abstract][Full Text] [Related]
37. Taxane-containing regimens for metastatic breast cancer.
Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
[TBL] [Abstract][Full Text] [Related]
39. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
[TBL] [Abstract][Full Text] [Related]
40. Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials.
Chen G; Guo Z; Liu M; Yao G; Dong J; Guo J; Ye C
Oncol Res; 2017 Nov; 25(9):1567-1578. PubMed ID: 28337954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
